Kymera Therapeutics (NASDAQ:KYMR) Given New $36.00 Price Target at B. Riley

Kymera Therapeutics (NASDAQ:KYMRFree Report) had its price target upped by B. Riley from $31.00 to $36.00 in a report released on Tuesday, Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other brokerages have also recently commented on KYMR. Oppenheimer reduced their target price on shares of Kymera Therapeutics from $53.00 to $52.00 and set an outperform rating for the company in a report on Friday, May 3rd. HC Wainwright reaffirmed a buy rating and issued a $46.00 target price on shares of Kymera Therapeutics in a report on Monday, June 17th. Seven analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Hold and an average target price of $42.09.

Get Our Latest Analysis on Kymera Therapeutics

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $39.44 on Tuesday. Kymera Therapeutics has a 1 year low of $9.60 and a 1 year high of $45.31. The company has a market capitalization of $2.42 billion, a PE ratio of -15.71 and a beta of 2.22. The company has a fifty day moving average of $33.79 and a two-hundred day moving average of $34.62.

Kymera Therapeutics (NASDAQ:KYMRGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.04. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The company had revenue of $10.30 million during the quarter, compared to the consensus estimate of $14.24 million. During the same quarter in the prior year, the firm posted ($0.70) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 8.4% on a year-over-year basis. On average, research analysts expect that Kymera Therapeutics will post -2.86 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Bruce Booth sold 453,960 shares of the stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the transaction, the director now directly owns 723,246 shares of the company’s stock, valued at $27,635,229.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Bruce Booth sold 453,960 shares of the stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the transaction, the director now directly owns 723,246 shares of the company’s stock, valued at $27,635,229.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Joanna Horobin sold 8,500 shares of the stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $32.99, for a total transaction of $280,415.00. The disclosure for this sale can be found here. Insiders sold 479,200 shares of company stock valued at $18,219,660 over the last ninety days. Corporate insiders own 15.82% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in KYMR. GSA Capital Partners LLP increased its holdings in Kymera Therapeutics by 141.2% in the third quarter. GSA Capital Partners LLP now owns 51,088 shares of the company’s stock valued at $710,000 after buying an additional 29,904 shares in the last quarter. Vanguard Group Inc. increased its holdings in Kymera Therapeutics by 4.9% in the third quarter. Vanguard Group Inc. now owns 3,925,213 shares of the company’s stock valued at $54,560,000 after buying an additional 182,125 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in Kymera Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,359 shares of the company’s stock valued at $187,000 after buying an additional 1,866 shares in the last quarter. SG Americas Securities LLC purchased a new position in Kymera Therapeutics in the fourth quarter valued at about $473,000. Finally, Clear Harbor Asset Management LLC purchased a new position in Kymera Therapeutics in the fourth quarter valued at about $255,000.

About Kymera Therapeutics

(Get Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

See Also

Analyst Recommendations for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.